Emergent Biosolutions, Inc.

XNYSHealth care

Last traded price · USD

$5.99

+1.53%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 14:43 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $5.90
Volume: 45
Day's high: —
Day's low: —

In brief

Emergent Biosolutions, Inc. is a health care company listed on the New York Stock Exchange, valued at about $307M.
Its shares closed at $5.90 on 4 Nov 2026, down 41.5% over the past year.
From India you can buy EBS in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Emergent Biosolutions, Inc. (EBS) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole EBS share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade EBS options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Behind SPY and its sector fund XLV over 1 year
1 month: −15.1% (SPY −1.6%, XLV +13.5%). 3 months: −21.8% (SPY −0.4%, XLV +15.5%). 1 year: −41.5% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: EBS, SPY and XLV · as of 4 Nov 2026
9.0 days to cover short interest
9.7M shares were sold short at the 15 Oct 2026 settlement, 18.9% of the 51.3M shares outstanding; covering them would take 9.0 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $5.90 was 9.6% below its 50-day average ($6.53) and 25.7% below its 200-day average ($7.94). It has closed below the 200-day for 174 sessions, since 27 Feb 2026. The 50-day average crossed below the 200-day on 9 Apr 2026, 145 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
16% of the way up its 52-week range
Closed at $5.90 on 4 Nov 2026: 58.0% below the 52-week high of $14.06 (7 Jan 2026) and 35.3% above the low of $4.36 (10 Aug 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Volume 2.2× its 30-session average on 4 Nov 2026
4 Nov 2026 volume of 2.3M shares was 2.2× the average of the 30 sessions before it (1.1M), as the price fell 5.6%. SPY traded 1.5× its own average that session.
Daily volume against a 30-session baseline · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−15.1%

6 months−35.2%

1 year−41.5%

Since Nov 5, 2021−82.2%

Newswire

About

Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.

Website

Notable moves

August 8, 2024
+46.85%
May 2, 2024
+70.98%
February 21, 2024
+78.29%

Newswire

About

Website

Notable moves

August 8, 2024
+46.85%
May 2, 2024
+70.98%
February 21, 2024
+78.29%

Emergent Biosolutions, Inc.

XNYSHealth care

Last traded price · USD

$5.99

+1.53%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 14:43 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $5.90
Volume: 45
Day's high: —
Day's low: —

In brief

Emergent Biosolutions, Inc. is a health care company listed on the New York Stock Exchange, valued at about $307M.
Its shares closed at $5.90 on 4 Nov 2026, down 41.5% over the past year.
From India you can buy EBS in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Emergent Biosolutions, Inc. (EBS) shares from India?

Do I need the price of a whole EBS share to invest?

How much can I invest in US stocks in a year?

Can I trade EBS options or futures?

Insights

Quotes run fifteen minutes behind.

Behind SPY and its sector fund XLV over 1 year
1 month: −15.1% (SPY −1.6%, XLV +13.5%). 3 months: −21.8% (SPY −0.4%, XLV +15.5%). 1 year: −41.5% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: EBS, SPY and XLV · as of 4 Nov 2026
9.0 days to cover short interest
9.7M shares were sold short at the 15 Oct 2026 settlement, 18.9% of the 51.3M shares outstanding; covering them would take 9.0 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $5.90 was 9.6% below its 50-day average ($6.53) and 25.7% below its 200-day average ($7.94). It has closed below the 200-day for 174 sessions, since 27 Feb 2026. The 50-day average crossed below the 200-day on 9 Apr 2026, 145 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
16% of the way up its 52-week range
Closed at $5.90 on 4 Nov 2026: 58.0% below the 52-week high of $14.06 (7 Jan 2026) and 35.3% above the low of $4.36 (10 Aug 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Volume 2.2× its 30-session average on 4 Nov 2026
4 Nov 2026 volume of 2.3M shares was 2.2× the average of the 30 sessions before it (1.1M), as the price fell 5.6%. SPY traded 1.5× its own average that session.
Daily volume against a 30-session baseline · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−15.1%

6 months−35.2%

1 year−41.5%

Since Nov 5, 2021−82.2%

Newswire

About

Website

Notable moves

August 8, 2024
+46.85%
May 2, 2024
+70.98%
February 21, 2024
+78.29%

Newswire

About

Website

Notable moves

August 8, 2024
+46.85%
May 2, 2024
+70.98%
February 21, 2024
+78.29%

Emergent Biosolutions, Inc.

Emergent Biosolutions, Inc. in brief

Behind SPY and its sector fund XLV over 1 year

9.0 days to cover short interest

Below its 50- and 200-day averages

16% of the way up its 52-week range

Volume 2.2× its 30-session average on 4 Nov 2026

Emergent Biosolutions, Inc.

Emergent Biosolutions, Inc. in brief

Behind SPY and its sector fund XLV over 1 year

9.0 days to cover short interest

Below its 50- and 200-day averages

16% of the way up its 52-week range

Volume 2.2× its 30-session average on 4 Nov 2026